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Abstract
Background: Melusin is a muscle specific signaling protein, required for compensatory hypertrophy response in
pressure-overloaded heart. The role of Melusin in heart function has been established both by loss and gain of function
experiments in murine models. With the aim of verifying the hypothesis of a potential role of the Melusin encoding gene,
ITGB1BP2, in the modification of the clinical phenotype of human cardiomyopathies, we screened the ITGB1BP2 gene
looking for genetic variations possibly associated to the pathological phenotype in three selected groups of patients
affected by hypertension and dilated or hypertrophic cardiomyopathy
Methods: We analyzed ITGB1BP2 by direct sequencing of the 11 coding exons and intron flanking sequences in 928
subjects, including 656 hypertensive or cardiopathic patients and 272 healthy individuals.
Results: Only three nucleotide variations were found in patients of three distinct families: a C>T missense substitution
at position 37 of exon 1 causing an amino acid change from His-13 to Tyr in the protein primary sequence, a duplication
(IVS6+12_18dupTTTTGAG) near the 5'donor splice site of intron 6, and a silent 843C>T substitution in exon 11.
Conclusions: The three variations of the ITGB1BP2 gene have been detected in families of patients affected either by
hypertension or primary hypertrophic cardiomyopathy; however, a clear genotype/phenotype correlation was not
evident. Preliminary functional results and bioinformatic analysis seem to exclude a role for IVS6+12_18dupTTTTGAG
and 843C>T in affecting splicing mechanism.
Our analysis revealed an extremely low number of variations in the ITGB1BP2 gene in nearly 1000 hypertensive/
cardiopathic and healthy individuals, thus suggesting a high degree of conservation of the melusin gene within the 
populations analyzed.
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Background
Melusin is a protein specifically expressed in heart and
skeletal muscles where it binds to the cytoplasmic domain
of β1 integrin, the membrane receptor anchoring the sar-
comeres to the plasma membrane [1]. The role of Melusin
in heart function has been established both by loss and
gain of function experiments by generating a Melusin-null
mouse lacking Melusin expression, and a Melusin trans-
genic mouse that over-expresses the protein in cardiomy-
ocytes. The phenotype of these mice clearly indicates that
Melusin is not required for heart development, sarcomere
organization or cardiac function in basal conditions [2].
Melusin ablation, however, strongly impairs the left ven-
tricle hypertrophy response to pressure overload, and dra-
matically accelerates the transition to cardiac dilation [2].
An opposite phenotype is observed when Melusin is over-
expressed in the heart of transgenic mice. The left ventri-
cles of these mice retain concentric compensatory hyper-
trophy with full contractile function and are protected
from dilation when subjected to long-standing pressure
overload [3]. These functional properties are accompa-
nied by protection from cardiomyocyte apoptosis and
lack of stromal tissue deposition, hallmarks of beneficial
heart remodeling. Interestingly, endogenous Melusin lev-
els are up-regulated during the initial phase of compensa-
tory hypertrophy in mice subjected to aortic banding, but
return to basal levels in heart that have undergone the
transition toward dilation [3].
Moreover, the expression and regional distribution of
Melusin in pressure-induced left-ventricular hypertrophy
due to aortic stenosis (AS) was investigated in humans [4]:
in normal hearts, Melusin was found in the myocytes with
a uniform regional distribution, while Melusin staining,
mRNA and protein were significantly decreased in AS
hearts. The reduction in Melusin expression parallels the
functional cardiac impairment in human AS.
At biochemical level, Melusin controls the phosphoryla-
tion of AKT and GSK3β in response to mechanical load. In
fact, lack of Melusin leads to impaired phosphorylation of
these proteins, while Melusin over-expression causes their
over-phosphorylation in response to mechanical stimuli
[2,3]. AKT is known to control phosphorylation of mTor,
p70S6 and GSK3β, three serine/threonine kinases respon-
sible for increased protein synthesis and cardiomyocyte
hypertrophy [5]. Evidences from different laboratories
[6,7] indicate that these molecules control increased car-
diomyocyte size and concentric hypertrophy and trigger a
beneficial compensatory cardiac hypertrophy.
Melusin is thus dispensable in physiological working con-
ditions, but is required to trigger the beneficial hyper-
trophic response, and prevent left ventricle dilation in
condition of exceptional mechanical overload. These
properties qualify Melusin as a gene potentially affecting
the evolution of the pathological status in cardiomyopa-
thies.
With the aim of verifying the hypothesis of a potential
role of the Melusin encoding gene, ITGB1BP2, in the mod-
ification of the clinical phenotype of human cardiomy-
opathies, we screened the entire coding region of
ITGB1BP2  gene (Xq12-q13) and the intronic flanking
regions looking for genetic variations possibly associated
to the pathological phenotype in three selected groups of
patients affected by hypertension and dilated (DCM) or
hypertrophic (HCM) cardiomyopathy.
Methods
Patients
For this study we analyzed genomic DNA from the follow-
ing patients and controls:
- 285 not related chronic hypertensive patients (average
age at first admission 59 years) without cardiac hyper-
trophic remodeling, from Naples Hospital - Hypertension
Diagnosis and Care Outpatient Clinic (HDCOC) of the
Federico II University, Naples, Italy.
- 106 not related patients with primary hypertrophic car-
diomyopathy (HCM) (average age at first admission 53
years) and 85 not related patients with primary dilated
cardiomyopathy (DCM) (average age at first admission 50
years) from the German Heart Institute Berlin, Germany
(DHZB).
- 41 not related patients with severe HCM or Hypertrophic
obstructive cardiomyopathy (HOCM) and 139 not
related patients with primary DCM from the Heart Centre
Göttingen, Germany (HCG).
- 80 blood donors (average age 45 years, 30 from IRCCS
Burlo Garofolo Blood Bank, Trieste, Italy and 50 from
Naples Hospital Blood Bank, Italy) and 192 subjects
(average age 50 years) from the DHZB with no history of
DCM, HCM or other cardiovascular diseases, all not
related were enrolled as healthy controls.
Additional information regarding patients' characteristics
are reported on table 1.
The groups of HCM and DCM patients from DHZB (Ber-
lin) have been examined also for sarcomeric gene muta-
tions in previous studies. In particular 6,5% of DCM
patients were found to carry mutations in beta-myosin
heavy chain (MYH7) and myosin-binding protein C
(MYBPC3) but not in troponin T (TNNT2), and alpha-tro-
pomyosin (TPM1) [8]. In addition, 32% of HCM patients
were found to carry mutations in myosin-binding proteinBMC Medical Genetics 2009, 10:140 http://www.biomedcentral.com/1471-2350/10/140
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C3 (MYBPC3), beta-myosin heavy chain (MYH7), cardiac
troponin T (TNNT2), cardiac troponin I (TNNI3) and
alpha-tropomyosin (TPM1). No disease-causing mutation
was found in cardiac troponin C (TNNC1) [9,10].
This project has been approved by the ethical committee
of the Department of Genetics, Biology and Biochemistry
of the University of Torino and informed consent was
obtained from all the participants.
ITGB1BP2 nucleotide variation scanning
Genomic DNA was extracted from peripheral whole
blood with the GenomePrep extraction kit (Amersham-
Pharmacia, Buckinghamshire, UK) following manufac-
turer's protocols.
PCR primers for ITGB1BP2 coding and flanking intron
sequences amplification were designed by using the
Primer Express 2.0 software (Applied Biosystems, Foster
City CA) on the basis of the genomic human sequence
(NM_012278; NC_000023). Primer sequences are
reported in Table 2. Sequencing (both strands) was per-
Table 1: Patients' characteristics
HDCOC (Naples) DHZB (Berlin) DHZB (Berlin) HCG (Goettingen) HCG (Goettingen)
Disease chronic 
hypertensive 
patients without 
cardiac 
hypertrophic 
remodeling
primary 
hypertrophic 
cardiomyopathy 
(HCM)
primary dilated 
cardiomyopathy 
(DCM) (no 
hypertension).
primary DCM severe HCM or 
Hypertrophic 
obstructive 
cardiomyopathy 
(HOCM)
# of patients analyzed 285 106 85 139 40
Age (year) 60.3 ± 0.8 (at echo) 53 ± 1.35 (at echo) 50 ± 1.0 (at echo) 58.2 ± 14.0 (at echo) 56.8 ± 21.2
Sex M/F (%) 66.1/33.9 61/39 77.6/22.4 80/20 62.5/37.5
BMI Kg/m2 27.6 ± 0.3 27.3 ± 0.42 26.3 ± 0.41 28 ± 5.5 27.9 ± 5.9
LVEDD (mm) 50.9 ± 0.3 46.0 ± 0.73 69.9 ± 1.0 63.5 ± 8.1 53.2 ± 6.7
LVEF (%) n.a. n.a. 24.8 ± 0.66 30.2 ± 9.9 49.4 ± 12.9
IVS (mm) 10.9 ± 0.11 18.1 ± 0.47 n.a. 10.6 ± 1.8 14.6 ± 3.7
PW (mm) 9.4 ± 0.07 n.a. n.a. n.a. n.a.
FS (%) 34.9 ± 0.3 33.7 ± 1.04 n.a. n.a. n.a.
SBP (mmHg) 160.7 ± 1.4 n.a. n.a. n.a. n.a.
DBP (mmHg) 100.7 ± 1.0 n.a. n.a. n.a. n.a.
Benign hypertension 
(%)
n.a.3 7n.a.2 1 . 5 7 . 5
Diabetes melliyus (%) 6 7.6 n.a. 7.15 2.5
Hyperlipoproteinaemi
a (%)
37.7 32 n.a. n.a. n.a.
Smoking history (%) 26.2 47 n.a. n.a. n.a.
Positive family history 
(%)
82 (Hypertension) 45 (HCM) 18 (DCM) 20 (DCM) 27.5 
(HCM or HOCM)
BMI: Body mass index. LVEDD: left ventricle end diastolic diameter. LVEF: left ventricle ejection fraction. IVS: inter ventricular septum. PW: 
posterior wall. FS: fractional shortening. SBP: sistolic blood pressure. DBP: diastolic blood pressure. n.a.: information not available.
Table 2: Primers used for PCR amplification of the 11 exons and intron flanking regions of the ITGB1BP2 gene
Exon Exon size (bp) Primer Forward Primer Reverse Amplicon size (bp)
1 63 TCAACCAACGCTTCCATG GGCTGTAAGATCACTCAG 214
2 49 AATTGGTCTGAGTGATCTT CAGATCAGCTTAGCTTCC 279
3 56 GGAAGCTAAGCTGATCTG CTAGTATAGATAAGGAGA 168
4 145 ATTTATGTACTTGGATTC CTAGTTCCCAGTCCTCAA 302
5 94 AACTAAATCACCACCCTT ATTGCCACTTCCACTAAA 180
6 55 TGAGTGGGGGGATGGATA AGGGCCTTGGTAAACCTA 227
7 70 CCCAGGATGTGATGCT GTAGGAAGATAATTCAACTGAATT 304
8 99 GCTATGAGGCTATGAGAC TGGCTATGTGGTACAGAG 273
9 113 CACGTGCATCATGAGAAC CTCTGCCTGTGAGATTGT 254
10 62 CAACCTGTGGATCATACC TCCAGTCTAGCCGCTCTT 222
11 227 CTCCTCCTCAGGTCATAA TCAACTGTCTGGTGTCAC 256BMC Medical Genetics 2009, 10:140 http://www.biomedcentral.com/1471-2350/10/140
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formed by using the Big Dye Terminator sequencing kit
(Applied Biosystems, Foster City CA). Sequence reactions
were run on an ABI 3130 Genetic Analyzer (Applied Bio-
systems) and the results handled with the Seqscape 1.0
software (Applied Biosystems).
Minigene splicing assay
Genomic DNA from patients with
IVS6+12_18dupTTTTGAG and 843C>T mutations and
from a wild-type control were amplified with appropriate
primers containing EcoRI and XhoI 5' site in order to gen-
erate fragments that contain Melusin gene sequence span-
ning from exon 5 to 7 (carrying the
IVS6+12_19dup18dupTTTTGAG mutation, primer Fw 5'-
CCGGAATTCATGAAGTCAGAGTTGCCT-3', primer Rev
5'-CCGCTCGAGCCCCTCATGGAAT-3') and Melusin
gene sequence spanning from exon 9 to 11 (carrying the
843C>T polymorphism, primer Fw 5'-CGGAATTCCGAT-
GCTCCCA-3', primer Rev 5'-TGCACTCGAGTCACAT-
TCTTTCAACT-3'). These fragments, following Klenow
kinasation, were cloned into Sma-digested pUC plasmid
for screening and sequencing. The fragments presenting
the correct sequence, obtained from these constructs, were
subcloned EcoRI/XhoI into the polylinker site of the
pCDNA3 vector. HeLa cells have been transfected with the
minigene constructs using the Effectene Transfection Kit
(Qiagen). RNA extraction has been performed after 24 h
following standard procedures, and reverse transcription-
polymerase chain reaction (RT-PCR) has been done with
primers pairing with SP6 and T7 regions in the plasmid
for the Melusin exon 5-7 minigene, and with specific oli-
gonucleotides pairing with the beginning of the exon 9
(primer Fw 5'-AGCATCTTGCCGCCATGATTGGC-3') and
an 11 exon internal region, close to the stop signal
(primer Rev 5'-TAGACATCAACTGTCTGGTG-3') for the
Melusin exon 9-11 minigene. RT-PCR products have been
analyzed on a 2% agarose gel and amplicon sequences
verified by direct sequencing.
Results
A total of 928 subjects including 656 patients from three
different groups and 272 controls were screened.
Only three nucleotide variations, two in hypertensive
patients of the HDCOC cohort and one in the HCM
patients group from the DHZB group were evidenced.
(Table 3).
The first variation is a C>T transition at nucleotide 843 in
the 5' region of exon 11 in close proximity to the preced-
ing intron. This is a silent substitution, which does not
modify the coded amino acid. The 843C>T single nucle-
otide polymorphism (SNP) was found in hemizygosis in
a male patient (#1) from HDCOC group characterized by
hypertension, eccentric cardiac remodeling and who suf-
fered from an ictus at the age of 66.
The second variation detected is a duplication,
IVS6+12_18dupTTTTGAG, occurring in intron 6 near the
5'donor splice site and found in heterozygosis in a female
patient (#2) from HDCOC group.
Both the 843C>T and IVS6+12_18dupTTTTGAG varia-
tions have not been found in healthy controls.
The third variation consists of C>T transition found in
heterozygosis at position 37 of exon 1 in one HCM female
patient (#3) from the DHZB group. The nucleotide
exchange leads to a substitution of a conserved amino
acid residue: histidine-13 to tyrosine. This patient devel-
oped HCM at age 38. This variation was not found in the
192 healthy controls from Germany as well as in the 80
Italian controls.
These were the only three nucleotide variations we
observed in the whole coding region and flanking
sequences of the ITGB1BP2 gene in the 930 individuals
investigated (658 patients and 272 controls).
Table 3: ITGB1BP2 nucleotide variations identified in this study
Patient/sex and origin Diagnosis Mutation Mutation status Mutation details
#1/M
HDCOC*
Hypertensive individuals with 
eccentric left ventricle 
remodeling
843 C>T
Silent mutation
Hemizygosis In exon 11, 8 bp downstream an 
exonic splicing enhancer - ESE - 
consensus sequence
#2/F
HDCOC*
Hypertensive individuals with 
eccentric left ventricle 
remodeling
IVS6+12_18dupTTTTGAG
intronic
Heterozygosis In intron 6 near the 5'donor splice 
site (10 bp downstream)
#3/F
DHZB$
Hypertrophic cardiomyopathy 
(HCM)
37 C>T
Missense mutation
Heterozygosis In exon 1, causes a His13Tyr 
substitution in the CHORD 
domain
* HDCOC: Hypertension Diagnosis and Care Outpatient Clinic of the Federico II University, Naples, Italy.
$DHZB: German Heart Institute, Berlin, Germany.
M = male
F = femaleBMC Medical Genetics 2009, 10:140 http://www.biomedcentral.com/1471-2350/10/140
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We then constructed the family pedigree (Figure 1) of the
three patients for which we found a mutation in the
ITGB1BP2 gene.
For patient #1 (proband II-1, Figure 1A) we were able to
identify 25 individuals through three generations. Unfor-
tunately, clinical information and cardiac phenotype were
lacking in 19 subjects. Three male patients (II-1 the
proband, II-7 and III-8), all characterized by eccentric
remodeling of the left ventricle, were hemizygous for the
843C>T SNP. Two females (III-6, III-7) with normal
echocardiogram parameters were heterozygous for the
mutation.
A: pedigree of patient's #1 family Figure 1
A: pedigree of patient's #1 family. Patient's #1, (II.1, the proband, indicated by the arrow) carries the 843C>T SNP in exon 
11. Subjects II.1, II.7, III.8 are hemizygous (single border grey line) for the mutated allele while subjects III.6 and III.7 are heter-
ozygous (single border black line). Black filled squares and circles: subjects with eccentric remodeling of the left ventricle; grey 
filled squares and circles: individuals with normal echocardiogram parameters. Information concerning clinical status, cardiac 
phenotype and ITGB1BP2 mutations are lacking in other subjects (empty circles and squares). B: pedigree of patient's #2 family. 
Patient's #2 (II.1, the proband, indicated by the arrow) carries the duplication IVS6+12_18dupTTTTGAG in intron 6. Subjects 
II.1 and III.1 are heterozygous (single border black line) for the mutated allele while subject III.2 is hemizygous (single border 
grey line). Black filled circle: subject with eccentric remodeling of the left ventricle; grey filled squares and circles: individuals 
with normal echocardiogram parameters. Information concerning clinical status, cardiac phenotype and ITGB1BP2 mutations 
are lacking in other subjects (empty circles and squares). C: pedigree of patient's #3 family. Patient's #3 (II.2, the proband, indi-
cated by the arrow) carries the C>T missense mutation at position 37 in exon 1. Subjects II.2 and III.1 are heterozygous (single 
border black line) for the mutated allele while II.6 and III.3 are hemizygous (single border grey line). Black filled squares and cir-
cles: subjects characterized by HCM. Empty circles and squares: not affected subjects. Some members of this family also carry 
a mutation in the 3'UTR of the troponin T gene (asterisk).BMC Medical Genetics 2009, 10:140 http://www.biomedcentral.com/1471-2350/10/140
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The family pedigree of patient #2 (proband II.1) is
reported in Figure 1B. We encountered only six individu-
als through three generations. Proband II.1 is hetero-
zygous for the IVS6+12_18dupTTTTGAG and is
characterized by eccentric remodeling of the left ventricle.
Two other members (one female III.1 and one male III.2)
of the family carrying the IVS6+12_18dupTTTTGAG (III.1
heterozygous; III.2 hemizygous) are characterized by a
normal echocardiogram.
The family pedigree of the HCM patient #3 (proband II.2)
is depicted in Figure 1C. The C>T transition at position 37
in the exon 1, leading to an alteration of a conserved
amino acid (histidin-13/tyrosine) in the CHORD 1
domain of the ITGB1BP2 gene (see Figure 2), was detected
in the proband II.2 (heterozygous), in her brother II.6
(hemizygous), her daughter III.1 (heterozygous) and her
son III.3 (hemizygous). Subjects II.2, II.6 and III.3 are
affected by HCM.
The proband II.2 and her two sons III.1 and III.3 were
known from previous analyses to carry a mutation in the
3'UTR of the troponin T gene (+6C/T 3'UTR). The tro-
ponin mutation was not present in the proband's hus-
band and healthy son III.2, as well as in the proband's
brother II.6 that was also characterized by HCM and the
C>T transition at position 37 in the exon 1.
We then performed an in-silico  analysis for both the
843C>T and IVS6+12_18dupTTTTGAG, with the aim of
testing the possible effects of the nucleotide variation on
exon splicing using the following softwares NNsplice
http://www.fruitfly.org/seq_tools/splice.html, Cryp-Skip
http://www.dbass.org.uk/cryp-skip/ and NetGene2 http:/
/www.cbs.dtu.dk/services/NetGene2/: the results
obtained indicated that the mutated sequences didn't
introduce or delete any donor or acceptor splice site. In
order to test the effect of the mutations in-vitro, we also
performed a minigene splicing assay for both 843C>T and
IVS6+12_18dupTTTTGAG, showing that the transcripts
obtained from the cells transfected with the wild-type
sequence and the mutated one, were the same both in
terms of length (Figure 3) and of sequence of transcripts.
The missense substitution C>T at position 37 resulting in
a H13Y substitution falls in a highly conserved region of
Melusin corresponding to the CHORD 1 domain charac-
terized by a unique Cys and His signature (Figure 2). To
investigate the putative functional consequences of this
mutation we performed a bioinformatics analysis by
using the PolyPhen software http://genetics.bwh.har
vard.edu/pph/index.html. The results of the analysis
(PSIC score difference = 1.530) indicate that the H13Y
substitution is predicted to be possibly damaging the pro-
tein structure/function.
Discussion
The results of different studies [2,3,11], suggested a role
for Melusin in cardiomyopathies as modifier gene, whose
inactivation worsens the pathology and/or increases sus-
ceptibility to heart failure in response to different patho-
logical conditions.
Analysis of the available data in the human genome data-
base http://www.ncbi.nlm.nih.gov/Genbank/ indicated
that Melusin ITGB1BP2 gene is highly conserved and only
a limited number of single nucleotide polymorphisms
have been described. In particular 35 SNPs are currently in
the NCBI SNPs database http://www.ncbi.nlm.nih.gov/
SNP/: 4 non-synonymous, 1 synonymous, 11 intronic, 19
Alignment of the primary sequence of melusin CHORD 1 domain in a number of mammalian species indicates the high degree  of conservation of the gene Figure 2
Alignment of the primary sequence of melusin CHORD 1 domain in a number of mammalian species indicates 
the high degree of conservation of the gene. The characteristic C (cysteine) and H (histidine) signature are highlighted. 
The position of the missense mutation detected in HCM patient causing His-13 > Tyr amino acid change is indicated by the 
arrowhead. (*) conserved residues (:) conserved substitutions.BMC Medical Genetics 2009, 10:140 http://www.biomedcentral.com/1471-2350/10/140
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in gene region. None of these SNPs, however, has been
correlated with human pathologies and their frequency in
the population has not been reported.
In this study we evidenced an extremely low number of
variations in the ITGB1BP2 gene in nearly 1000 hyperten-
sive/cardiopathic and healthy individuals, thus suggesting
a high degree of conservation of the melusin gene, within
the populations analyzed. In fact, only three genetic vari-
ants were detected in a total of 656 patients and 272
healthy controls screened by direct sequencing analysis;
moreover the three variations have been found in three
different patient and not in any control.
The 843C>T transition was found in a patient (#1) from
HDCOC group of hypertensive patients that developed
eccentric remodeling of the left ventricle. When analyzing
the patient's family, three male subjects, all characterized
by eccentric remodeling of the left ventricle, were
hemizygous for the 843C>T SNP while the remaining
three individuals with standard echocardiography profile
showed the wild type DNA sequence. This SNP falls in the
exon 11 coding region but is a silent substitution not
affecting the coded amino acid. The sequence surround-
ing the 843C>T SNP, however, falls 3' to a consensus
motif for an exonic splicing enhancer sequence (ESE),
short nucleotide sequences that can stimulate splicing and
regulate alternative splicing [12]. ESE sequences are
present in most, if not all, exons, including constitutive
ones and are thought to serve as binding sites for specific
serine/arginine-rich (SR) proteins that promote exon def-
inition by recruiting the splicing machinery. Nonsense,
missense and even translationally silent mutations occur-
ring in such ESE sequences can inactivate genes by induc-
ing the splicing machinery to skip the mutant exons.
Similarly, coding-region single-nucleotide polymor-
phisms might cause phenotypic variability by influencing
splicing accuracy or efficiency [12,13]. This hypothesis has
been verified by a functional assay: we performed an anal-
ysis of the 843C>T SNP, by using a minigene system in
order to test if the 843C>T SNP may affects Melusin gene
splicing; our results indicate that the nucleotide substitu-
tion seems not to affect the splicing, similarly to what sug-
gested by an in silico analysis we performed. The length
and sequence of the mutated transcript were the same of
the wild-type ones. However, these results should be cau-
tiously considered, since they are just an in vitro model
that may not completely reflect what happens in vivo in
the patients, and the Hela cell line model (available to us)
is quite different from the cardiomyocytes. Taking in
account these limitations, we can not exclude the possibil-
ity that, in the in vivo context of muscle cell, the mutation
A: Analysis of the splicing pattern by RT-PCR of the wild-type and IVS6+12_18dupTTTTGAG constructs after transfection in  the HeLa cell line: both constructs reproduce the same splicing pattern (amplicon length 382 bp) Figure 3
A: Analysis of the splicing pattern by RT-PCR of the wild-type and IVS6+12_18dupTTTTGAG constructs after 
transfection in the HeLa cell line: both constructs reproduce the same splicing pattern (amplicon length 382 
bp). Mk: 100 bp molecular ladder; WT: wild-type sample; MT: IVS6+12_18dupTTTTGAG sample. B: Analysis of the splicing 
pattern by RT-PCR of the wild-type and 843C>T SNP constructs after transfection in the HeLa cell line, showing that both 
constructs reproduce the same splicing pattern (amplicon length 432 bp). Mk: 100 bp molecular ladder; WT: wild-type sample; 
MT: 843C>T sample.BMC Medical Genetics 2009, 10:140 http://www.biomedcentral.com/1471-2350/10/140
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detected can alter the splicing introducing stop codon(s)
which can ultimately lead to nonsense-mediated decay of
the aberrant transcript, as already reported for mutations
in other genes [14,15]. Testing this hypothesis requires
analysis of Melusin transcripts in samples of skeletal mus-
cle biopsies from patients, which, unfortunately, were not
available for our study.
The second mutation detected in a hypertensive patient
(#2) of the HDCOC group was the duplication
IVS6+12_18dupTTTTGAG, occurring near the 5'donor
splice site of intron 6. Such duplication was found in het-
erozygosis in a female patient presenting a modest cardiac
remodeling. However, it was also found in an unaffected
male as well as in an unaffected female, so this mutation
reasonably does not correlate with the eccentric remode-
ling of the left ventricle and it is likely to represent an
additional polymorphism of the Melusin gene whose
association with the cardiac pathology is unlikely.
Similarly to what done for the 843C>T, also for the
IVS6+12_18dupTTTTGAG we performed an in silico and a
minigene splicing assay, without evidencing any differ-
ence in the transcript between the wild-type and the
mutated sequence. However, the same arguments dis-
cussed for the 843C>T SNP, can be applied also to this
mutation.
The third mutation detected is a C>T transition at position
37 in the exon 1 of the ITGB1BP2 gene and represents a
missense mutation causing an amino acid change from
His-13 to Tyr in the protein primary sequence. Such muta-
tion falls in a highly conserved region of the Melusin mol-
ecule corresponding to the first CHORD domain
characterized by a unique Cys and His signature [2] (Fig-
ure 2). The tertiary structure of Melusin CHORD domains
has not been solved yet, and this fact restrains the possi-
bility to predict the effect of the mutation. However, the
substitution of an His residue, which is highly conserved
and is part of the signature of the mammalian melusin
CHORD 1 domain (Figure 2), strongly suggest that such
mutation can modify the structure/function of the pro-
tein. This hypothesis, moreover, is also supported by pre-
liminary bioinformatic analysis. The His/Tyr mutation in
exon 1 was detected in heterozygosity in female patients
II.2 and III.1 and in hemizygosity in male patients II.6 and
III.3. No biological samples other than DNA were availa-
ble from the subjects, thus impeding the possibility to per-
form functional study on the protein. The effect of this
mutation remains to be disclosed, and it should also be
noticed that while three of the patients (II.2, II.6, III.3)
that presented the mutation are affected by HCM, one of
the two heterozygote females (III.1) is not. This family
also carries (II.2, III.1, III.3) an additional mutation in the
3' UTR of troponin T gene, whose molecular impact on
the HCM status is unknown as well.
Conclusions
In the present study we evidenced an extremely low
number of variations in the ITGB1BP2  gene in nearly
1000 hypertensive/cardiopathic and healthy individuals,
thus suggesting a high degree of conservation of the
melusin gene, at least within the populations analyzed:
only three genetic variants were detected in a total of 930
individuals. This very low frequency of polymorphisms is
surprising in a gene whose ablation in an animal model
system does not cause phenotypic alterations in basal
conditions [2]. In fact, such strong sequence conservation
is usually typical of genes whose alteration causes vital
defects in embryos.
Nonetheless, in spite of a great conservation of the
ITGB1BP2 gene, we have identified three new polymor-
phisms in three pedigrees that behave as private SNPs
whose impact on the cardiovascular pathologies remains
to be defined. Notwithstanding the fact that a preliminary
functional assay on the role of two of these variations
showed no effect, given the limitation of this approach,
we believe that the impact of the 843C>T substitution in
particular should deserve further functional investiga-
tions, since it has been evidenced in hemizygosis only in
the affected members of a family with hypertension and
eccentric left ventricle remodeling. It remains opened the
question whether this variation should be considered as
"private" variation specific of the family where it was asso-
ciated with the clinical phenotype or if other subjects
affected by CMD not considered in the present study
could also present this variation. The last hypothesis is
that 843C>T SNP could be simply a "private" marker that
associated with the clinical phenotype in the family con-
sidered.
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